Abemaciclib Plus Endocrine Therapy Approved for Early Breast Cancer

The FDA has approved abemaciclib (Verzenio®, Eli Lilly and Company) in combination with endocrine therapy consisting of an aromatase inhibitor or tamoxifen as adjuvant therapy for patients with hormone receptor (HR)–positive, human epidermal growth factor receptor 2 (HER2)–negative, node-positive early breast cancer with a high risk of recurrence. Abemaciclib, the first CDK4/6 inhibitor to be approved in the adjuvant breast cancer setting, is indicated for patients with a Ki-67 score of ≥20%. In...
Continue reading

CTC Count-Driven Treatment Improves Survival in HR-Positive, HER2-Negative Metastatic Breast Cancer

Using circulating tumor cell (CTC) count to determine whether chemotherapy or endocrine therapy is used improves survival outcomes compared with clinically determined treatment in patients with hormone receptor (HR)-positive, HER2-negative metastatic breast cancer, according to the results of the open-label, randomized phase 3 STIC CTC trial published today in JAMA Oncology. The investigators, led by François-Clément Bidard, MD, PhD, Professor of Medicine at the University of Paris-Sac...
Continue reading

In HER2-Negative Metastatic Breast Cancer, Adding CDK4/6 Inhibitor to Endocrine Therapy Helps Survival

 Endocrine therapy plus cyclin-dependent kinase 4 and 6 (CDK4/6) inhibitors improved overall survival, progression-free survival, and objective response rate for patients with hormone receptor–positive, HER2-negative metastatic breast cancer, according to results of a meta-analysis published recently in JAMA Oncology. The finding supports continued use of endocrine therapy plus CDK4/6 inhibitor combinations in clinical trials. The investigators, led by first author Jinming Li, BD, a pr...
Continue reading


Get the latest updates delivered to your inbox!

Follow Us

Copyright © 2021 Oncology Data Advisor. All rights reserved.